The treatment options for CLL have increased over the past decade; notably, the BTK inhibitor and the BCL-2 inhibitor venetoclax in both relapsed/refractory as well as treatment-naïve CLL patients have shown impressive progression-free and overall survival rates [2,3,4,5]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.